References

  1. Friedewald S, Rafferty E, Rose S, et al. (2014). Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography. Journal of the American Medical Association (JAMA), 311(24), 2499-2507
  2. Zuley M, Bandos A, Ganott M, et al. “Digital Breast Tomosynthesis versus Supplemental Diagnostic Mammographic Views for Evaluation of Noncalcified Breast Lesions.” Radiology. 2013 Jan; 266(1):89-95.
  3. Skaane P, Bandos A, Gullien R, et al. “Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program.” Radiology. 2013 Apr; 267(1):47-56.
  4. Rose S, Tidwell A, Bujnock L, et al. “Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study.” American Journal of Roentgenology. 2013 Jun; 200(6): 1401-1408.
  5. Brodersen J, Siersma V. “Long-Term Psychosocial Consequences of False-Positive Screening Mammography.” The Annals of Family Medicine 2013 Mar;11(2):106-15.
  6. BreastScreen Victoria. Available at: https://www.breastscreen.org.au/Breast-Screening/The-Facts.aspx. Accessed December 2014.
  7. Ciatto S, Houssami N, Bernardi D, et al. “Integration of 3D Digital Mammography with Tomosynthesis for Population Breast-Cancer Screening (STORM): A Prospective Comparison Study” The Lancet Oncology.
  8. Cancer Australia, Breast Cancer in Australia: An overview. Cancer Series Number 71. October 2012. Australian Institute of Health and Welfare, Canberra. Cat. no. CAN 67.
  9. Cancer Council Australia. Available at: www.cancer.org.au/about-cancer/types-of-cancer/breast-cancer.html Accessed December 2014.
  10. National Breast and Ovarian Cancer Centre. Breast cancer risk factors: a review of the evidence. National Breast and Ovarian Cancer Centre, Surry Hills, NSW, 2009.
  11. Australian Radiation Protection and Nuclear Safety Agency. Available at www.arpansa.gov.au/services/ndrl/ ndrlFactsheet.cfm. Accessed July 2016.
  12. BreastScreen Australia. Available at: http://cancerscreening.gov.au/internet/screening/publishing.nsf/Content/breastscreen-n-you-html. Accessed May 2015.
  13. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 2011;103(15):1179-1189.
  14. Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013;15(6):R104.
  15. FDA. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ MedicalDevices/MedicalDevicesAdvisoryCommittee/RadiologicalDevicesPanel/UCM325901.pdf. Accessed June 2016.
  16. FDA PMA submission P080003/S001 physician labelling.
  17. Bernardi D, Pellegrini M, Valentini M et al. “The STORM II (Screening with Tomosynthesis or Mammography II) Trial: Interim Comparison of Screen-reading Strategies in Population Breast Screening.” (paper presented at the annual meeting of the Radiological Society of North America, Chicago, Il, December 2014).
  18. Durand M, Raghu M, Geisel J, et al. “Synthesized 2D Mammography + Tomosynthesis: Can We See Clearly?” (paper presented at the annual meeting of the Radiological Society of North America, Chicago, Il, December 2015).
  19. Choi J, Han B, Ko E, et al. “Comparison with Two-Dimensional Synthetic Mammography Reconstructed from Digital Breast Tomosynthesis and Full Field Digital Mammography for the Detection of T1 Breast Cancer.” European Radiology. Epub 2015 Dec.
  20. Zuckerman S, Conant E, Weinstein S. “Impact on Recall Rates Following Implementation of Synthesized 2D Mammography in Digital Breast Tomosynthesis Screening.” paper presented at the annual meeting of the Radiological Society of North America, Chicago, IL, December 2015).
  21. Zuley M, Guo B, Catullo V, et al. “Comparison of Two-dimensional Synthesized Mammograms versus Original Digital Mammograms Alone and in Combination with Tomosynthesis Images.” Radiology. 2014 Jun;271(3):664-71.
  22. Skaane P, Bandos AI, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014;271(3):655-63.

Disclaimers

Genius 3D MAMMOGRAPHY exams are only available on the Selenia® Dimensions® breast tomosynthesis system by Hologic.

In Australia a 3D MAMMOGRAPHY exam is typically used as a diagnostic mammogram, usually performed at private radiology clinics and hospitals for high risk patients or women with abnormalities or symptoms, e.g. a lump or other suspicious finding. A GP or surgeon referral is required detailing clinical indications.

WEB-00431-AUS-EN, Rev. 003 ©2016 Hologic, Inc. All rights reserved. Specifications subject to change without notice. Hologic, Dimensions, Genius, 3D, 3D MAMMOGRAPHY, Selenia, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. 3D MAMMOGRAPHY is marketed as Genius 3D MAMMOGRAPHY in the U.S. and Australia. Site updated May 2016.

Hologic (Australia) Pty Ltd, Level 4, 2-4 Lyon Park Rd, Macquarie Park NSW 2113. Tel. +61 2 9888 8000. ABN 95 079 821 275.

Genius Customer Centre

Genius Customer Centre - Password reset

Genius Customer Centre

Thank you for submitting your request for a password. Once we verify your details we will email your login details to you. Please allow 1-2 working days to receive your login information.

Genius 3D MAMMOGRAPHY Customer Centre Usage Agreement

Contingent upon the limited use of the Image(s) and Templates contained within the Genius 3D MAMMOGRAPHY Customer Centre provided by Hologic, Inc. and affiliates (together “Hologic”), you are hereby authorized to use, reproduce and distribute the contents provided:

  1. You agree to credit any product Images as having been provided ‘courtesy of HOLOGIC, Inc. and affiliates’.
  2. You agree that whenever you use a Hologic trademark, product name, graphic or Image, you will attach a proper trademark attribution notification to the foremost reference;
  3. You warrant and guarantee that you shall use the Images and Templates only in promotion of HOLOGIC, Inc. products used within your practice;
  4. You warrant and guarantee that you shall not modify any Image except as expressly consented to in writing by HOLOGIC;
  5. You warrant and guarantee that you shall not utilize the Images or Templates in any manner that could reasonably be foreseen to disparage or cause disrepute to HOLOGIC and you shall provide immediate notice to HOLOGIC in the event you become aware of any such use;
  6. You acknowledge and agree that, while at the time of publication, HOLOGIC endeavors to make all materials accurate and regulatory compliant, HOLOGIC makes no representations or warranties regarding the information provided;
  7. You warrant and guarantee that you shall not license, transfer, or sell the Images and Templates or any copies of the Images and Templates to any person or entity; and
  8. You release HOLOGIC, its successors, assigns, licensees, employees, agents and representatives from any and all claims arising from your use of the Images and Templates.
  9. Any use of the Images and Templates must comply with all regulatory approvals, laws and Government regulations where applicable.

HOLOGIC may terminate this agreement at any time, for any reason, with immediate effect upon notice to you at the address provided below. Upon termination of this agreement, you shall immediately cease reproducing, distributing or otherwise utilizing the Images and Templates and shall return all copies of the Images and Templates to HOLOGIC.

Arbitration, Choice of Law and Enforcement. Any controversy or claim arising out of or related to this Agreement will be settled by binding arbitration, by a single arbitrator, administered by the Australian Arbitration Entity and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. Any arbitration under this Agreement will be held in Sydney, Australia and the arbitrator shall have no authority to award punitive, consequential, or other damages not measured by the prevailing Party’s actual damages. Each Party will bear its own costs and expenses and an equal share of the arbitrators’ and administrative fees of arbitration. This Section and this Agreement will be governed by and interpreted in accordance with the laws of Australia. If any of the provisions of this Section or this Agreement are held to be invalid, illegal or unenforceable, the validity, legality, and enforceability of the remaining provisions will not be affected or impaired.

Please fill in your details below:

Dear healthcare professional,

Thank you for your password enquiry for the healthcare professional section of www.genius3Dmammography.com.au.

It is a requirement of the Therapeutic Goods Administration that this section of the website is available to qualified healthcare or medical practitioners only.

Please provide the information requested below to enable Hologic to verify you and provide you with access.

Your details will not be kept on file, they are for verification purposes only

As soon as Hologic has confirmed your details, we will respond with the password.

Alternatively, if you have further queries, please call Hologic Australia on 1800 264 073 or email to australia@hologic.com